The startup develops precision RNA-based biomarker platforms that combine immunomodulatory monoclonal antibodies with immune checkpoint inhibitors to enhance the efficacy of cancer therapies. This approach aims to improve long-term survival rates for cancer patients by enabling healthcare providers to deliver targeted and effective treatment options.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies often lack the precision to target tumor cells effectively, leading to off-target effects and limited long-term survival rates. The efficacy of immunotherapies can be hindered by immunosuppressive mechanisms within the tumor microenvironment.
Solution
The company is developing precision RNA-based biomarker platforms designed to enhance the efficacy of cancer therapies. These platforms combine immunomodulatory monoclonal antibodies with immune checkpoint inhibitors, aiming to improve targeted delivery and minimize off-target effects. By modulating the immune response within the tumor microenvironment, the approach seeks to improve long-term survival rates for cancer patients. The technology enables healthcare providers to deliver targeted and effective treatment options based on individual patient biomarkers.
Target Audience
The primary audience includes healthcare providers, oncologists, and pharmaceutical companies focused on developing and delivering targeted cancer therapies.
Features
- RNA-based biomarker identification for precise patient stratification
- Immunomodulatory monoclonal antibodies to enhance immune response
- Combination with immune checkpoint inhibitors for synergistic therapeutic effect
- Targeted delivery mechanisms to minimize off-target effects